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Clinician Relates Thickness of Stage I
Melanoma to Prognosis and Treatment
by Jesus E. Medina, MD, Department of Head and Neck
Surgery
This article is a summary of an article that first appeared in
Current Therapy in Otolaryngology: Head and Neck Surgery 11,
George A. Gates, ed. B. C. Decker, Inc., New York, 1984.

In the last four decades, the incidence of malignant melanoma
has steadily increased, and it continues to do so. Approximately
20% of all malignant melanomas originate in the head and neck.
The only proven curative treatment for a primary melanoma of the
head and neck is surgical excision of the lesion before deep
invasion into the dermis and lymph node metastasis have
occurred. It is therefore imperative that the otolaryngologist and
head and neck surgeon become acquainted with the biologic and
clinical characteristics, as well as the specific treatment guidelines, of this rather capricious malignancy.
Melanomas of the head and neck usually occur between the
fourth and sixth decades of life. Although rare during childhood
and adolescence, melanomas of the head and neck in these age
groups have the same biologic behavior as they do in adults and
should be treated accordingly. Prolonged exposure to sunlight
appears to play a role in the etiology of melanoma, especially in
individuals with fair and freckled skin and light hair and eyes.
The clinical characteristics of early primary melanomas of the
skin are far too diverse to be pathognomonic. A melanoma
usually has irregular borders and an irregular surface, which may
appear bumpy or scaly; the lesion may be one or more colors that
vary from shades of pink to brown, dark blue, or black. Any
pigmented lesion that has recently changed in size, color, or
appearance or, more important, has begun bleeding or has
developed satellites (small growths around the lesion) should be
removed for diagnosis. An excisional rather than an incisional
biopsy should be performed whenever possible so that the

pathologist may scrutinize the entire lesion.
Once the diagnosis of melanoma is made, the extent of the
disease must be estimated to plan appropriate treatment. The
physician should determine the patient's general condition, the
exact location of the lesion, the presence or absence of ulceration
of the lesion, and• any pigmentation that may indicate the
presence of atypical melanocytes in the junction of the dermis
and epidermis or satellite lesions in the surrounding skin . To
determine the status of the cervical and regional lymphatics, the
physician should carefully palpate the neck and the preauricular,
retroauricular, suboccipital, or buccinator regions, depending
upon the location of the primary tumor. Examination of patients
with melanomas in the lateral and posterior aspects of the lower
portion of the neck should include palpation of the axilla.
Besides an accurate histologic diagnosis, determination of the
morphology, the anatomic level of invasion, and the actual
thickness of the melanoma is important. The presence of
inflammatory infiltrates at the base of the melanoma should also
be noted.
The laboratory evaluation of each patient with malignant melanoma includes a complete blood count, determination of liver
enzymes, and a chest radiograph. When the melanoma is thicker
than 0.76 to 1.0 mm, liver, spleen, and brain scans are obtained.
These tests not only allow proper staging of disease but also
provide baseline values for future examinations. In the presence
of palpable adenopathy, suggestive of metastatic melanoma, the
initial evaluation may be extended to include computed tomo-

graphic (CT) scan of the lungs and brain and a bone scan.
The staging system for malignant melanoma currently in use at
this institution is as follows: stage 0: melanoma confined to the
epidermis; stage I: primary melanoma only (no metastasis),
Continued on page 6

Shown above left is a stage I melanoma. Note the irregular borders, bumpy and scaly surface, and variety of shades characteristic of this
tumor. The above center photo illustrates a stage I melanoma of the skin of the forehead with satellites, small surrounding growths that often
accompany this lesion. Shown above right is a stage Ill melanoma of the skin of the neck. The disease has metastasized from the primary
site, the black mole, to the postauricular nodes.

MOPP Chemotherapy Proves Effective for
Infants and Children with Brain Tumors
Combination chemotherapy with nitrogen mustard, vincristine
sulfate (Oncovin), procarbazine, and prednisone (MOPP) can
effectively control the growth of brain tumors in infants and young
children, according to a recent study at UT MDAH.
This finding is especially significant because no adequate
treatment was previously available to large numbers of young
children who had brain tumors. Brain tumors constitute one-third
of all childhood cancers, the peak incidence occurring in children
at 5 years of age.
According to Jan"van Eys, MD, PhD, head of the Division of
Pediatrics, who conducted the study, "Until recently, the prospects of treating children less than 5 years old with brain tumors
were grim; if patients did survive, they were severely handicapped by the treatment." Conventional treatment has consisted
of surgery and radiotherapy. After surgery for brain tumors,
residual disease often exists. Wide margins cannot be taken
around the tumor for fear of excising much normal brain tissue.
To control residual disease, central nervous system radiotherapy
is required. Central nervous system irradiation in very young
children, however, often produces skeletal dwarfing and impairs
intellectual functioning. In infants, brain irradiation frequently
causes microcephaly, resulting in severe mental retardation . "If
the skull does not grow the brain cannot grow, and intellectual
development is stunted," Dr van Eys explained. "Consequently,
we are especially reluctant to irradiate babies with the required
doses."

Because recent studies have shown that chemotherapy alone
does not retard physical or intellectual development in young
children, Dr van Eys searched for a chemotherapy combination
that would control brain tumor growth in this patient group until
such children were old enough to receive salvage radiotherapy if
required. Encouraged by results with MOPP chemotherapy as
adjuvant treatment and salvage therapy for older children with
brain tumors, Dr van Eys decided to use this combination as
primary treatment or as adjuvant treatment after surgery in a
group of children with brain tumors who were all less than 4 years
old.
Of all drugs used to treat children with brain tumors, MOPP is
the least toxic and yet has proven to be highly effective for
various types of brain tumors, especially average-grade gliomas
and medulloblastomas, which comprise 80% of all brain tumors in
children. MOPP causes mild myelosuppression (the dose-limiting
side effect) in comparison to that caused by cisplatin, another
drug used for children with brain tumors. In addition, MOPP,
unlike other drug combinations, does not induce vomiting in
infants.
Fifteen patients were entered in the study, 6 boys and 9 girls.
All patients had partial surgical excision of their tumors, either for
tissue diagnosis or treatment; no patient had prior treatment other
than surgery, neither radiotherapy nor chemotherapy. Patient
ages were: 7 patients, less than 1 year old ; 4 patients, between 1
and 2 years; 2 patients, between 2 and 3 years; and 2 patients,
between 3 and 4 years. The types of tumors treated and the
number of patients with each were: medulloblastoma, 6 patients;
ependymoma, 3 patients; spinal cord astrocytoma, 3 patients;
supratentorial astrocytoma, 1 patient; undifferentiated tumor, 1
Continued on page 7
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The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
Department of Nursing

Oncology Nursing Conference VI
September 12-14, 1984
Hyatt Regency Hotel Downtown
Houston, Texas
Chairperson: Anita K. Verges, RN, BSS, Department of
Nursing
Designed for the oncology nurse, the conference will cover
the topics of substance abuse and the nurse, occupational
exposure of nurses, nursing intervention in managing
pain, and computer software in nursing.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
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Gene Probes Used in Leukemia Diagnosis
Researchers at UT MDAH have isolated gene probes shown to
have diagnostic potential for chronic lymphocytic leukemia (CLL),
acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and possibly
others.
Grady Saunders, PhD, Department of Biochemistry and Molecular Biology, and co-workers have produced these diagnostic
probes using recombinant DNA technology; their goal is to find
probes useful in the diagnosis and classification of all leukemias.
The ability to accurately diagnose the various types of leukemia is essential for the proper treatment of each. Most
diagnostic tests are based on phenotypic differences among the
cells of different leukemias. Subtle phenotypic changes, however, are many times impossible to detect, and diagnostic
accuracy is thus precluded.
The more accurate gene probe method relies on fundamental
genetic differences among the cells of various leukemias and
normal cells. These genetic differences are apparent in the cells'
messenger RNA populations. The messenger RNA carries
instru\'.:tions for making proteins from DNA to the protein-synthesizing machinery in the cytoplasm. Deviations in RNA instructions
may cause abnormalities in cellular functioning and the production of neoplastic disease. These RNA instructions should be
characteristic for each type of cancer, including each leukemia.
To produce a diagnostic probe to detect the RNA instructions
of certain leukemias, a DNA copy of each messenger RNA
molecule in a white blood cell from a leukemia patient is made.
The first series of probes isolated at UT MDAH were made from
the white blood cells of a CLL patient, and other probes have
been made from CML cells. Recombinant DNA technology is
then used to splice pieces of the DNA into the genes of bacteria.
Each bacterium, grown separately, forms a clone of identical
cells, each cell containing an exact copy of the original DNA. The
clones are then amplified to provide the large quantities of DNA
necessary for testing against normal cells and cells of various
leukemias.
Identification of a diagnostic probe involves using single
strands of the cloned DNA to find corresponding RNA in normal
and leukemic cells. The cloned DNA is tagged with a radioactive
label and then placed on a filter that contains immobilized RNA
from normal cells or from cells of a certain type of leukemia. The
single-stranded DNA attach to matching RNA (complementary
RNA), forming hybrid molecules. Th~ unattached DNA is then
washed off of the filter. The relative abundance of complementary
RNA is measured by the amount of radioactivity present, which is
proportional to the number of hybrid molecules. A piece of cloned
DNA is considered to have potential diagnostic value if its complementary RNA is more abundant in the cells of certain leukemias as compared to cells of other leukemias and normal cells.
One such clone, C-A3, for example, has been found to be
diagnostic for chronic phase CML and AML when the Philadelphia (Ph 1 ) chromosome, a cytogenetic abnormality, is present. In
testing this probe in normal and leukemia cells, 10 of 11 Ph 1 positive specimens, all either AML or CML cells, showed high C-A3
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This illustration of a slot blot analysis shows levels of hybridization
of RNA of normal and leukemia
cells with the C-A3 probe. The
darker the blot the greater the
number of hybrid molecules. In
this analysis, all patients with
chronic myefogenous leukemia
(CML) and acute myelogenous
leukemia (AML) had the Philadelphia-positive (Ph 1 +) chromosome. All CML and AML samples
showed some degree of reactivity, yet the RNA in normal cells did
not react. In further testing, the
C-A3 probe was also found to be
specific for Ph 1 - CML. These
results indicate that the C-A3
probe is diagnostic for CML and
Ph 1 + AML.

Normal
White Cells #3
Normal
White Cells #4

RNA levels; however, no hybridization was detected in any of the
other samples.
The C-A3 probe and others found to have diagnostic value are
stored on filter paper in a "library" of diagnostic probes. Each will
be made readily available for use in patients to identify their
specific leukemias when the experimental phase of the project is
complete. The original tagging method for developing a specific
probe will also be used in making diagnoses.
In screening with gene probes, several have been found to be
specific for two or three types of leukemia; in this case, in
diagnostic testing, the tagging procedure can be repeated in cells
of a particular leukemia using different probes. Through a
process of elimination, the RNA expression pattern specific to
one leukemia can be determined.
To date, at least 10 probes have been developed for use in
diagnosing CLL, ALL, CML, and AML. According to Dr Saunders,
"The primary advantages of using these gene probes are their
specificity and ability to identify leukemic cells in small numbers."
Although still experimental, this method when used routinely in
the diagnosis of leukemia patients should allow for accurate and
early detection of disease at its onset and at recurrence.
(Physicians desiring additional information should write or call
Grady Saunders, PhD, Department of Biochemistry and Molecular Biology, MDAH Box 117, The University of Texas M. D.
Anderson Hospital and Tumor Institute at Houston, 6723 Bertner
Avenue, Houston, Texas 77030 (713) 792-2690.-ED)
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Researcher Associates High Potassium, Low
High potassium intake can significantly decrease one's cancer
risk, according to a 10-year study conducted at UT MDAH.
Birger Jansson, PhD, Department of Biomathematics, who
conducted the study, has correlated low cancer rates with high
environmental K concentrations and with a high intracellular K/Na
ratio in individuals, as affected by diet, age, altitude, and
hyperkalemic diseases.
The study was initially undertaken to find an explanation for the
extremely low colorectal cancer rate in Seneca County, New
York, which is located in the U.S. area with the highest colorectal
cancer rate. In a preliminary study, conducted at UT MDAH for
the National Large Bowel Cancer Project, that ranked the 3056
U.S. counties according to colorectal cancer rate, Seneca was
found to have a rate 1000 ranks less than its neighbor counties.
Seneca's total rate for all malignant neoplasms was also significantly lower than the rates of all New York counties.
The unique geochemical makeup of Seneca County was found
to be the most probable explanation for its low rate. Seneca
obtains its drinking water from two deep glacial lakes that
penetrate the underlying salt strata, causing the sum of the
concentrations of K and Na salts to be between 1O and 20 times
higher than in other lakes in the state. Also, the K/Na ratio was
found to be higher in Seneca's lakes than in other New York
lakes. High K salt concentrations were thought to lower the
cancer rate because of findings indicating the vital role of
intracellular K salt in cellular functioning and in protection against
cell damage caused by carcinogens. "Researchers believe that
an intracellular imbalance of K and Na salts resulting in a surplus
of Na and a K deficiency may lead to distortion of genetic
information and ultimately to the formation of neoplasms," Dr
Jansson explained.
Results obtained in Seneca County were confirmed in a
nationwide study correlating environmental K salt concentrations
with cancer rates of various U.S. areas. Cancer rates in areas
with salt lakes or salt playas with high K concentrations were,
without exception, lower than those of nonsalty areas. Utah,
which contains the Great Salt lake, has the lowest cancer rates
in the U.S. The K salt concentration in this lake was found to be
even higher than in Seneca's lakes, and the K/Na ratio three
times higher than that of the lakes of Seneca.
Dr Jansson substantiated these findings by correlating the
cancer rates of 20 countries with estimated total dietary intake of
Kand Na in each country. Data was obtained from the Organization for Economic Cooperation and Development, an international organization that records annual intake per capita of more
than 100 food commodities for each of its member countries.
Intake of Na positively and K negatively correlated with high
cancer rates for all malignancies and sites of disease, and a high
K/Na ratio was always associated with low cancer rates. The
greatest correlations were inverse correlations between the K/Na
ratio and breast cancer (r = -0.80, p <0.0001) and the K/Na
ratio and colorectal cancer (r = -0.68, p <0.0001 ). Other
dietary studies support these findings.
Increased incidence of breast cancer associated with high
intake of polyunsaturated fat may also be explained by a low
4
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Fig. 1. Relation between breast cancer mortality per 100,000
population per year and dietary K!Na ratios in each member
country of the Organization for Economic Cooperation and
Development. Those countries with low K!Na ratios generally
have high breast cancer mortality rates. (The Na concentration is
underestimated in this figure; table salt and salt used in
preservation and preparation of food is not included.)

K/Na ratio in the body, Dr Jansson added. High intake of
polyunsaturated fats has been found to increase intracellular Na
and decrease K. Licorice, an additive widely used in tobacco
products, is also a known potassium depleter and causes a
decline in the intracellular K/Na ratio; licorice thus may contribute
to the high cancer rate among smokers.
On the other hand, vitamins A and C, both anticarcinogens,
have been found to increase the intracellular K/Na ratio. Low
cancer rates have also been associated with high-fiber vegetarian diets comprised of vegetables and fruits often low in Na and
high in K. According to Dr Jansson, vegetarians have a dietary
K/Na ratio four times higher than that of meat eaters.
With this evidence, Dr Jansson then speculated that the
changes in the intracellular K/Na balance with age may contribute
to increasing cancer rates in older populations In aging~,"-'-a~□~i~
□f=la~w~----
of Na into the cells and a corresponding cellular K reduction, and
eventual excretion of K from the body, occurs. In fact, some
researchers believe that cellular leakage of K may contribute to
cell aging. Dr Jansson correlated cancer rates with total body K
and with the total body K/Na ratio calculated for six age groups,
18 to 25, 25 to 35, 35 to 45, 45 to 55, 55 to 65, and 65 to 85 years.
Data indicating total body K, including intracellular K (96% of total
body K) and extracellular K (4% of total body K), and K/Na ratios
for each age group were obtained from a related study. As
expected, Dr Jansson found negative correlations; as cancer
incidence increased with each older group, total body K and the
K/Na ratio decreased. The correlation coefficient of cancer
incidence and total body K in men was - 0.92 and in women was
-0.89; the correlation coefficient of the K/Na ratio and cancer
rate was - 0.80 for women; the information was not available for
men.
July-September 1984
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Sodium Intake with Decreased Cancer Rates
To further substantiate his theory, Dr Jansson was able to
correlate cancer rates with altitude, which affects the intracellular
K/Na balance. The lower oxygen pressure at higher altitudes
changes the acid base balance in cells of individuals causing a
flow of extracellular K into the cells and an outflow of intracellular
Na. This results in a more alkaline cellular acid base and a higher
intracellular K/Na ratio than at sea level.
Dr Jansson compared cancer rates for various cancer sites in
low and high elevation areas in the U.S. included in the Third
National Cancer Survey (TNCS). The average of the rates for
each cancer site in the eight low regions was divided by the rate
in Colorado, the only high elevation area included in the TNCS.
Most values were over 1, representing cancers for which the low
areas had higher rates than the high area. Particularly high
values were found for cancers of the mouth (men 1.47, women
1.31 ), esophagus (men 2.04, women 1.43), rectum (men 1.39,
women 1.49), and lung (men 1.38, women 1.34). The high/low
area values for all sites were 1.14 and 1.1O for men and women
respectively. Further calculations showed that cancer rates fo;
the mouth, esophagus, lung, and larynx, organs most exposed to
air pressure, are most dependent on elevation. "The difference in
oxygen pressure between sea level and high altitudes is greatest
in those organs most exposed; the difference gradually decreases as the air moves toward the venous blood," Dr Jansson
explained.
Dr Jansson cited data from another researcher's work, conducted in Papua, New Guinea, that clearly support his findings.
Papua, New Guinea, is comprised of a highland area, in which no
one lives below an altitude of 1,600 m, and a lowland area,
reaching from sea level to about 1,300 m. Although diet is the
same in both the highlands and lowlands and the percentage of
persons older than 45 is greater in the highlands, the overall
(M)

cancer incidence rate in the lowlands for men is 2.5 and for
women is 2.0 times higher than in the highlands. For oral and
respiratory cancers, the incidence rates in the lowlands are 1O
times higher for males and 7 times higher for females than in the
highlands. Results from other geographic locations support these
findings.
Certain diseases affecting the intracellular K/Na ratio are also
associated with cancer risk. In a study of patients with Parkinson's disease, a hyperkalemic disease, Dr Jansson discovered
that among 406 patients only 9 men and 9 women developed
cancer (p <0.0001, nonmelanoma skin cancers excepted); 10
developed nonmelanoma skin cancer (p < 0.0001 ), and 65
developed benign tumors. In a study of Addison's disease, a
hyperkalemic-hyponatraemic disease, no incidence of cancer
occurred out of a total population of 108 patients (p < 0.01 ).
Schizophrenia, another hyperkalemic disease, has also been
related to a low incidence of cancer.
In contrast, Cushing's syndrome, a hypokalemic disease, is
associated with cancer of the lung, pancreas, thymus, ovary, and
thyroid, as well as tumors of the pituitary and adrenal glands.
Crohn's disease, another hypokalemic disease, increases the
risk of intestinal cancer. Alcoholism may increase the risk of
cancer because it causes hypertension, which results in a low
intracellular K/Na ratio. Patients with diabetes have total body K
levels 1o to 20% below normal levels; these patients have also
been reported to be at increased risk for pancreatic cancer. Other
hypokalemic diseases associated with increased cancer risk are
renal disease, osteoporosis, obesity, and cirrhosis.
Dr Jansson cited several animal experiments that have validated the above findings. In one experiment, when KCSN
(potassium thiocyanate) was added to the drinking water of mice,
it reduced mammary neoplasms from 50% to less than 20%. In
another study, KCI added to the drinking water of rats that were
challenged by the carcinogen 1 ,2-dimethylhydrazine reduced
colon tumor incidence by 29% and small intestine tumors by 87%
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It has also been found that in populations of individuals who
practice two independent carcinogenic activities such as smoking
and drinking the effect on the cancer rate is synergistic rather
than additive. Even if the intracellular K/Na concentration in
individuals is a linear function of the dose of each one of the
carcinogenic agents, the effect, the cancer rate, grows faster than
linearly .
This study should provide some indication why certain diets,
geographical areas, and diseases are associated with high
cancer rates. Such information may prove useful in understanding the etiology of cancer and in finding ways to prevent the
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Fig. 2. Relation between cancer mortality of white males for all
disease sites and average elevations calculated for each of 48
U.S. states. Note that the relation is hyperbolic rather than linear,
indicating a sudden increase in cancer rates below a certain
altitude.
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disease, Dr. Jansson said.
(Physicans desiring additional information should write or call
Birger Jansson, PhD, Department of Biomathematics, MDAH
Box 46, The University of Texas M. D. Anderson Hospital and
Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030 (713) 792-3392.-ED)
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Melanoma
Continued from page 1

including an intact primary lesion or multiple primary lesions;
stage II: local recurrence, defined as recurring melanotic lesions
within 3 cm of the primary site (satellitosis); stage Ill: regional
metastasis involving intradermal lesions 3 cm from the primary
site, with or without regional nodal disease; stage IV: distant
hematogenous metastasis, including cutaneous, visceral, or
nodal disease or a combination of the above.
For many years, treatment of the patient with stage I malignant
melanoma has been controversial. The controversy concerns the
extent of the excision of the primary lesion and the indications for
elective node dissection.
Information accumulated in the literature over the past 14 years
has allowed us to recognize, within the broad category of stage I
melanomas, several subgroups of melanomas that have similar
behavioral characteristics and similar prognostic indicators. From
these data, guidelines for the treatment of stage I disease have
evolved that are currently in use at UT MDAH and other
institutions. These guidelines relate actual thickness of stage I
tumors to prognosis and to the need for elective cervical lymph
node dissection. Other factors, such as tumor location, tumor
ulceration, and anatomic level of invasion are also taken into
account.
Patients with melanoma less than 0.76-mm thick have a good
prognosis, regardless of the location of the lesion. Treatment of
these paJients consists of adequate excision of the primary lesion
alone. A regional lymph node dissection is not indicated.
Less than 20% of patients with melanomas 0.76- to 1.50-mm
thick develop regional lymph node metastasis. Therefore, the
recommended treatment for this group is adequate surgical
excision of the primary lesion and observation of the regional
lymphatics. However, the following characteristics of these relatively thin lesions have been associated with more aggressive
tumor behavior and a worse prognosis: location of the lesion in
the posterior aspect of the scalp or the neck, ulceration of the
lesion, nodular configuration of the melanoma, and melanoma
invasion of the reticular dermis or deeper areas. Whenever one
or more of these factors is present, elective regional node
dissection is performed, provided that the general condition of the
patient is good and the lymph nodes at risk of involvement are
predictable.
Patients with melanomas 1.51- to 4.0-mm thick have a higher
incidence of regional lymph node metastasis, yet the incidence of
systemic metastasis is fairly low. All studies suggest that this
group of melanoma patients benefits the most from elective node
dissection. Therefore our treatment for these natients consists of
adequate surgical excision of the primary lesion and regional
node dissection.
Patients whose melanomas are thicker than 4.0 mm have poor
prognoses. Distant metastasis develops in a high percentage of
the patients. The organs most commonly involved are the lung,
bone, and brain. To improve prognosis, therapy for these patients
should be aimed at controlling systemic disease with adjuvant
chemotherapy, immunotherapy, or both after surgical excision of
the primary tumor. Although elective regional node dissection is

a
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not likely to influence the patient's survival, it may be justified as a
staging procedure.
An adequate surgical excision of a primary melanoma should
remove the entire lesion and any areas of junctional activity or
melanoma in situ. The extent of surgical resection depends on
the location and size of the lesion, the condition of the skin
around it, and the judgment of the surgeon. The extent of regional
lymph node dissection also depends upon the location of the
primary lesion.
Patients who develop stage II melanomas have local disease
or dermal metastases within 3 cm of the primary tumor, which has
usually been removed previously. After the presence of distant
metastasis has been reasonably excluded, the area of recurrence is widely excised. Elective cervical node dissection is
performed when the lesion is laterally located and the direction of
nodal drainage is predictable.
The treatment of disseminated melanoma has generally been
unsuccessful. Dimethyltriazenoimidazole carboxamide (DTIC)
Continued on page 8

The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
Department of Pharmacy

Sixth Annual Pharmacy
Symposium
On Cancer
Chemotherapy
October 7-10, 1984
Shamrock Hilton Hotel
Houston, Texas
Chairpersons: William H. Puckett, Jr, MS, MBA, RPh,
Department of Pharmacy, and Sharon Bronson, MS, RPh,
Department of Pharmacy
This symposium is designed to present principles of
cancer patient care to the pharmacist and allied health
professional. Topics covered in presentations, workshops,
and advanced course modules include pain management,
interteron tnerapy, regional perfusion ana inlracavitary
therapy, pharmacologic oncology practice, and the pharmacokinetics of chemotherapy.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
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MOPP Chemotherapy
Continued from page 2

patient; and neuroectodermal neoplasm, 1 patient. The spinal
fluid was found to contain tumor cells in 4 patients, but no patient
had bone marrow invasion, skeletal lesions, or extra-axial metastasis.
All patients were given MOPP chemotherapy once every 4
weeks on the following dose schedule: nitrogen mustard, 6
mg/m 2 of body surface area intravenously on days 1 and 8;
vincristine, 1.4 mg/m2 intravenously on days 1 and 8; procarbazine, 50 mg/m2 orally on day 1 and 100 mg/m 2 orally per day
from days 2 to 10; and prednisone, 40 mg/m 2 orally per day from
days 1 to 1O tapered off to zero dosage over the following 3 days.
In infants under 6 months and in those suffering side effects, the
first course was adjusted downward to 50%.
The categories and criteria for response to MOPP were: 1)
unequivocal response-anatomical evidence of tumor regression of at least 50% as determined by computed tomographic
(CT) scan (in those patients whose bulk tumors were not
surgically excised); absence of dependence on dexamethasone,
a steroid used for brain edema caused by brain tumors; and
neurologic improvement as determined by physical examination.
Sustained response for each criterion was required for at least 3
months; 2) probable response-impovement of two of the three
criteria above and stabilization of the third, again with sustained
response for 3 or more months; 3) no response-progression of
signs and symptoms and continued steroid dependence, or
response for less than 3 months.
Seventy-three percent (11 of 15 patients) of the patients
responded to treatment. Five patients achieved unequivocal
response, and 6 patients, who subsequently suffered relapse
(occurring from 7 months to 3 years after treatment) , achieved
probable response. Four patients exhibited no response to
treatment. A ll nonresponding patients and those suffering relapse
after MOPP treatment received either radiotherapy or cisplatin,
depending on the age of each child.
At the last follow-up (1-31-84), 5 patients had died of their
disease within 2 years of treatment: 2 of the 6 patients suffering
relapse after MOPP chemotherapy and 3 of the 4 nonresponding
patients. Ten patients (entered in the study at various times) with
survivals ranging from 8 months to 8 years were alive. Survival
was determined in each patient from the time MOPP chemotherapy was administered to the time of last follow-up. Survival
times for these 1O patients are: O to 1 year, 1 patient who has
achieved unequivocal response; 1 to 2 years, 4 patients, 2 having
unequivocal response; 2 to 3 years, 3 patients; 3 to 4 years, no
patient; 4 to 5 years, 1 patient who has achieved unequivocal
response; and 5 or more years, 1 patient having unequivocal
response. These findings imply that MOPP chemotherapy is able
to control the growth of brain tumors in a substantial number of
infants and young children for prolonged periods.
The side effects of the MOPP chemotherapy regimen used in
this study have been minimal. The majority of children suffered
mild myelosuppression, alopecia, and nausea; those over 2
years of age experienced vomiting . The primary side effect of
MOPP in the treatment of other malignancies has been the
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occurrence of second malignancies. In this study, 1 patient
suffered acute myelogenous leukemia after therapy. However, Dr
van Eys said, the second malignancy occurred so soon after
treatment that chemotherapy was probably not the cause. In
addition, recent psychological testing has shown that intellectual
functioning in these children was not impaired by the MOPP
treatment.
The results of this study show that MOPP chemotherapy in
young children with brain tumors can effectively delay, and in
some cases may even preclude, the necessity for salvage
radiotherapy. As Dr van Eys explained, "We have taken a giant
step forward; for the first time, we have a rational organized
approach to the treatment of infants and young children with brain
tumors."
(Physicians desiring additional information should write or call
Jan van Eys, MD, PhD, Department of Pediatrics, MDAH Box 87,
The University of Texas M. D. Anderson Hospital and Tumor
Institute at Houston, 6723 Bertner Avenue, Houston, Texas
77030 (713) 792-6620.-ED)
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Melanoma
Continued from page 6

has been associated with a definite antitumor response in only 14
to 25% of these patients. Although the median survival for
responders is 4 to 5 months longer than for nonresponders, the
median survival for all treated patients is 3.5 to 4.5 months. The
addition of other antitumor agents has not substantially improved
the response rate or survival of patients with stage IV melanoma
over that achieved with DTIC. Certainly, the poor prognosis and
lack of effective treatment for patients with stage IV melanoma
encourage the investigation of new agents with possible activity
against this tumor. At UT MDAH, the effectiveness of such drugs
as bisantrene, homoharringtonin, and interferon is currently being
evaluated.
Melanomas that originate in the mucosal surfaces of the upper
aerodigestive tract represent approximately 7% of all melanomas
of the head and neck. The anterior nasal septum, the palate, and
the alveolar ridges are the most common sites of disease origin.
Although regional lymph node metastasis occurs in only 20 to
25% of patients, the prognoses in most cases are dismal. Less
than 30% of them survive longer than 5 years. The pattern of
failure is usually that of local recurrence followed by systemic
metastasis. Our treatment of these patients consists of surgical
excision of the primary lesion. Elective cervical lymph node
dissection is not recommended . Given their unfavorable prognoses, these patients should be considered for experimental
adjuvant treatment with radiation therapy, systemic chemotherapy, or both.
Because of the high incidence of distant metastases in patients
with malignant melanoma, many studies of adjuvant therapy
immediately following primary treatment have been reported
recently. A number of investigators have used adjuvant immunotherapy with bacillus Calmette-Guerin vaccine and levamisole.
The results have been discouraging. However, the use of specific
immunotherapy with viral oncolysates as adjunctive therapy in
patients with malignant melanoma appears promising. Researchers have recently reported excellent results using a Newcastle
disease virus lysate of malignant melanoma cells, following
therapeutic lymphadenectomy, in a group of patients with clinically palpable lymph node metastasis (stage II/ melanoma).
Although this was not a prospective randomized study, the
results have been striking ; therefore, this technique merits further
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evaluation. At UT MDAH , we are currently investigating as
adjuvant therapy vitamin A and its derivatives, the retinoids,
which have an inhibitory effect on melanoma cells in vitro, as well
as a possible antineoplastic effect in vivo.
Finally, the potential role of radiation as adjuvant therapy after
surgery in the local-regional control of malignant melanoma is
currently undergoing re-evaluation. Historically, malignant melanoma has been considered a radioresistant tumor. However,
several recent experimental and clinical studies have suggested
that radiation has a better effect on malignant melanoma cells
when given in a few large-dose fractions (> 500 rad) instead of
the conventional dose fractionation of daily doses of approximately 200 rad.
In spite of these recent advances, melanoma continues to be a
highly lethal disease. Because cure is certain only for those
patients with superficial tumors, early diagnosis and treatment of
melanoma is of primary concern to all physicians. Improvement in
the outlook for patients with melanoma also depends upon
increased public awareness of early signs of the disease.
(Physicians desiring additional information shou ld write or call
Jesus E. Medina, MD, Department of Head and Neck Surgery,
MDAH Box 69, The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030 (713) 792-6920.-ED)

Cancer Rehabilitation
Covered in New Book
Cancer Rehabilitation, edited by Albert E. Gunn, MB, BCb,
LLB, Medical Director of the Rehabilitation Center, is now
available (Raven Press, New York, 1984, 240 pages, $44.00).
This interdisciplinary volume offers pragmatic guidance in major
areas of cancer rehabilitation . State of the art techniques as well
as the conceptual foundations of cancer rehabilitation are covered by well-known authorities in this field.
The book stresses the importance of a rehabilitation program
geared to the patient's immediate and varied needs. Topics
covered in depth include sexual rehabilitation, psychiatric care,
nutritional support, enterostomal therapy, home hyperalimentation, speech pathology, and pain control. Chapters on the
rehabilitation of patients with head and neck cancer and with
laryngectomies are also included.
July-September 1984

